ML20214D979
| ML20214D979 | |
| Person / Time | |
|---|---|
| Site: | 03019521 |
| Issue date: | 01/28/1987 |
| From: | Riedlinger B NRC OFFICE OF INSPECTION & ENFORCEMENT (IE REGION V) |
| To: | |
| Shared Package | |
| ML20214D981 | List: |
| References | |
| 50-19913-01, 50-19913-1, NUDOCS 8705210582 | |
| Download: ML20214D979 (4) | |
See also: IR 05000199/2013001
Text
{{#Wiki_filter:twwwjww_mememumumm&4_&pummmmmm,memmppummmmmmmmmmmmmmmmmmmmq dicr 370 1 4
PAGE OF PAGES (3 83) U.S. NUCLE AR QEGULATOQY COMMISSION Amendment No. 11 I MATERIALS LICENSE Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93 -438), and Title 10, f Code of Federal Regulations, Chapter 1, Parts 30,31,32,33,34,35,40 and 70, and in reliance on statements and representations g heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct. l source, and special nuclear material designated below; to use such material for the purpose (s) and at the place (s) designated below; to t deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This {I license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is II subject to all applicable rules, regulations and orders of the Nudear Regulatory Commission now or hereafter in effect and to any conditions specified below. I Licenwe ! In accordance with application ,1 l dated December 17, 1986 i l- Ketchikan General Hospital 3. License number 50-19913-01 is amended in { its entirety to read as follows:lj i 2. 3100 Tongass Avenue .r . ,cs I Ketchikan, Alaska 99901 4. Expirationdate January 31, 1992 I ' g li 5. Docket or 3d-19521 ' [ > Reference No. 6. Ilyproduct, source, and/or 7. Chemical and/or physleal 8. Maximum amount that licensee l i , special nuclear material form
- may possess at any one time
lL f F ( under this license - A. Any byproduct material A. 'Any radiopharmaceutical A. -As necessary for uses I listed in Groups I and listed in Groups I and II authorized in L !! of Schedule A, of Schedule A. Section ( Subitem 9.A. j , ~ L 35.100 of 10 CFR 35 Section 35.100 of , 10 CFR 35 ', I ' I ,3 . s . B. Any byproduct material B.. . Any forni listed ;in Group III B. '2 curies of each ( listed in Group 111 , - of Schedule A', Section 35.100 . byproduct material t Section 35.100 of ~ J authorized in l of Schedule A, '; of 10 CFR 35. - J ~' ~ '~ Subitem 6.0. 10 t I ' * CFR 35 ' t ' > ' I ! C. Any byproduct material 10.. Any 'C. 3 millicuries of each l ' listed in Section 31.11(a) , byproduct material t of 10 CFR 31 authorized in
- L
, Subitem 6.F. t It !E I 'l I'L ll L lii I L L i kI 8705210502 870120 !L HE05 LIC30 ll 50-19913-01 PDR lr l 1 . l $L(01 I u...................................................;....a . - - . - - . - . - . . - . - - -
L----b-------------------------------------------------y C Form 374A U.S. NUCLEAR cEGULATORY COMMISSION 2 4 l ,,oe y ,,oes Licen,e number I 50-19913-01 l MATERIAL.S LICENSE
" * " * * " " " SUPPLEMENTARY SHEET l 030-19521
I Amendment No. 11 l l l 6. BYPRODUCT, SOURCE, AND/0R 7. CHEMICAL AND/0R PHYSICAL 8. MAXIMUM AMOUNT THAT LICENSEE I SPECIAL NUCLEAR MATERIAL FORM MAY POSSESS AT ANY ONE TIME l UNDER THIS LICENSE i l D. Xenon-133 D. Gas or gas in solution D. 50 millicuries I that is the subject of I an active (i.e., not l withdrawn or terminated) i "NewDrug$pp]jcation" l (NDA) GpproVed by)FD ' or I (~ Nq * active (i .e;. , not. / a I I Ithdrawn, terminated'or:')/g y2 I on " clinical hold") s " Notice of Claimed s g i 'y Investigational Exemption 4 i h for a New Drug" (IND) that 7 ) , I - 4[f K?hasbeenacceptedby}#/DA 4, A I MVN I , E. Phosphorus 32 /U E.'[Abysolubl6ihosp teY E.O10 millicuries l ' f that,has ,been[ manufactured, O i 4 . labeled.jpackaged',jandle b Q('c' distr 1b~uted'inaccordance/, ~ 23 p j- ij sitha!specificElicense, issued j i (j) 7 N Wdl,<; pursuant (tolSection 32l72e f v o c r I Missuedk'32 'o'rM ' pecific license 4 10 CFR s O- % I ' to alnia~nUfscturer by anh l M m b [4 AgreBinent(State' pursuant to ,. y', equivalent"st' ate regulations M i /4 4(Jjpp
- /
M, A I F. Americium 241 SFs Sealed sources l F. Not to exceed ,/ (AmershamAMC.24) 94 14 millicuries [i s o M, per source 4 , 9. Authorized use > > A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 l of Title 10, Code of Federal Regulations. > I B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed p in Group III of Schedule A, Section 35.100 of Title 10. Code of Federal I Regulations. C. In vitro studies. l l ' O. Blood flow and pulmonary function studies. > >
E. For treatment of polycythemia vera, leukemia and bone metastases. > p f F. Anatomical marker, , > > YmundstamamumUnimamumumusumDmiUm&diamusumDminUmumadmQuGEhUnimQsumDaw wm imUinUmGm imimpaGuaris:wYfun=G=nmD - - - - - - - - - - - - - - -- -
inu n u m $m u m a n m a m m e - z u m - - - - m = = m m m m m m m m m m a - - - m a m m a = = - - - - a n u m; l NRC Form 374A U 1 NUCLEAR C8.GULATORY COMMISSION 3 4 l ,,og o, ,,oes I I License number l l ! MATERIALS LICENSE I SUPPLEMENTARY SHEET I 0 1 21 I l l l l Amendment No. 11 p I I I l l CONDITIONS l l 10. Licensed material shall be used only at Ketchikan General Hospital, 3100 l l l Tongass Avenue, Ketchikan, Alaska. I I I I 11. Licensed material listed in Item 6 above is authorized for use by, or under the l l supervision of, the following individual (s) for the materials and uses l indicated: l i I I h l * Q $ s'1,j I, and III I Zeke L. Hendricks, M.D. l I g In vitro uitudies l I l Xenon 133 ~ Q, I i Phosphorus 32 as, soluble phosphate for l treatment of poly?ythemia vera, i l %g - leukemia, and bon etastases i I Arthur K. Harris,. 8. 1 I,$$ IIIM- I D GroupsI,)'u'diei; In vitro st I l /% ":M ' CXenon{33ff$ O l jM:? /gPhosphoruss32Jassoluble+phosphatefor l .* - i - . (3$ ' [r 't i.% [% reatinent- of polycythemi t' i I T60k$mlahand bo,ne meta' stases l l b D k,$ }[ 7 g y-{y!Y11 da/,jp/, j N%g gV O I I fn c de 70 l Groups 'nd'III > I I John C. Jowett, M:D. I !I M Vitfo studies' D I E's)M(Q'*pl}~ % %C h l h 2v Ei3iiTJ3 y o N l h') & QR ,r p i , I 12. The Radiation Protecti6n Officer \\fo(the ~de'tivitjesjauthorfzgd by this license i I is Dr. Zeke L. Hendrfcks; 'C{Jg
- /
M i I
- f/
, %) l l 13. For a period not to excee(sixty (60) days in any caliiSar year, a visiting l 1 l physician is authorized to use wlicensed njater,ialjfor human use under the terms , I of this license, provided the visitihg physician:P l ' I i I A. Has the prior written permission of the hospital's Administrator and its l l Radiation Safety Committee, and l l k B. Is specifically named as a user on a Nuclear Regulatory Commission license i i I authorizing human use, and i I I I C. Performs only those procedures which the physician is specifically i I authorized to perform pursuant to a license issued by the Nuclear I l Regulatory Comission. l l l l The licensee shall maintain for inspection by tne Commission copies of the p I written permission specified in A. above and of the license (s) specified in B. p I and C. above for a period of 5 years from the date permission is granted under i I A. above. I I > I I I I I I bisasmw-----i ri r-----T-,iirr- . ., ,. m ,,,,, 1 . , ,,,,,. . c;7 Tc m 7TT 7 7.,m m2 -. _ - _ _
-. . m - L------------------A------------------------------y RC Form M4A U.S. NUCLEAR REGULAT;TtV COMMISSION l 4 4 I p,g g, PAGES License number l MATERIALS LICENSE ! ~ ~ 0 019b1 I ' " SUPPLEMENTARY SHEET I I ' J Amendment No.11 1 . l l l CONDITIONS (continued) ! I 14 The licensee is authorized to hold radioactive material with a physical I half-life of less than 65 days for decay-in-storage before disposal in ordinary I trash provided: l A. Radioactive waste to be disposed of in this manner shall be held for decay ! 9REGg ! aminimumoften(10)hal 1 8. Prior to disposal as(norrsif' waste, radioactive waste shall be surveyed to I determinethatitq*radioactivitycannotbedisting'ufshedfrombackground. l All radiation labels'shall be rerroved or obliteratedg
g T A I C. Generator columns shall be segregated so that they-may be, monitored p separatelytk'e'n'sure'decaytobackgroundlevelsip/r.idr to-disposal. I / TQ M in/a.c/$ I The licensee may j, transport licensed matefiil,tionfof) Radioactive' Material".co l 15. of10CFRPart7(,k,Packaginj;and'fransporta " l Oil ( j% d Ihsp '# 16. Except as specif)cally pr,ovided(oth'efwisTTn tfiisilicense,, the illcensee shall y procedures contained in.;theldocuine;withwthenstatements drepresentations, and conduct its prograq in accordance i The Nuclear Regulatory Coimils'sfon'Mfelg{nclu'dijigfa6s enclosbresPlisted nts i
~ ulations. shall7 govern unless the N correspondence are Taore restridive 'tha ?the $the_Jicensee's ipplication and! statements,represenkatio'ns)andq@edursQih g# , egulations. C" J j Q \\\\ .,(Jj j' hA ' p 9/ \\') A. Application dated De& ember 17, 1986; i , 0 M i I B. Model ALARA Program 'c66tained in Append x ofRegulatoryGuideIg!8(Rev.1) gb l M. 4 R , 4 p ,d , <,r r'
. , _ FOR THE UfS'. NUCLEAR REGULATORY COMMISSION i l original signed by B. A. Riedlinger i I Date January 28, 1987 By , Beth A. Riedlinger g Health Physicist (Licensing) i Nuclear Materials Safety Section i Region Y l i l b 1 p
- ' ,,
i f W , f h w..............--.... _ . ...--.....--...-. _ -- .,,.J }}